NEW YORK, NY / ACCESSWIRE / June 9, 2016 / Joint Pain Relief Codes strengthens the bones and eases symptoms of joint pain. The exercises increase balance and sense of where joints are located. They focus on strengthening and improving control of muscles, specifically the muscles which influence posture.

Helps Ease Symptoms Of Joint Pain

Joint pain can be caused by severe injury affecting any of the bursae, ligaments or tendons encircling the joint. A serious injury can affect the bones, ligaments and cartilage within the joint. Pain within the joint is a common cause of ankle pain, shoulder pain as well as knee pain. There are a number of signs and symptoms linked with joint pain which include joint redness, joint warmth, joint swelling, joint tenderness, stiffness, weakness, limping, locking of the joint and loss of range of motion of the joint.

EXCLUSIVE: Unusual Stretch Treats Joint Pain in Minutes (NBA Secrets Exposed)

There is a newly launched program named “Joint Pain Relief Codes” developed by Jonathan Bender which contains a number of exercises that help ease symptoms of joint pain. A number of people with mild to chronic joint pain face difficulty in doing regular exercises. This reduced activity level in people with joint pain results in lessened muscle strength and after all can lead to heightened ache. However, regular exercises help ease the symptoms of joint pain.

The stretches recommended inside this program claim to improve a person’s daily function, scale down their depression and fatigue, turn down pain and improve sleep. However, people should not use joint pain as an excuse not to exercise. Instead, they should make it their reason to get moving with these expert recommended stretches and exercises for better results.

Click Here To Find Out How To Get Relief From Knee, Back, Neck & Other Joint Pains

Moreover, these exercises help stretch a person’s muscles and soothe their joints. The exercises along with stretches help control a person’s weight, boost mood and it is good for their overall health and well-being.

Increases Balance And Improves Body Awareness

The stronger a person’s muscles are, the less strain there is on their joints which is why they should not be discouraged towards these stretches as they are a great way to get stronger and boost muscle mass. However, people can begin calmly, slowly and raise their intensity bit by bit. They should aim for two to three days a week, doing a number of different exercises and stretches that work different large muscle groups across their body.

In addition to that, when a joint and its encircling muscles are affected by mild to severe joint pain, the result is often impaired balance and an increased risk of falling due to which a number of people grumble about their knees giving out with physical activity.

Click Here To Download Joint Pain Relief Codes PDF

The creator behind JointPainReliefCodes explicates that the types of exercises and stretches recommended inside this course are examples of exercises that provide relaxation and improve body awareness. They can increase balance and sense of where joints are located.

Additionally, these exercises focus on strengthening and improving control of muscles, specifically the muscles which influence posture. Moreover, people do not always have to hit the gym for a good workout. The program comes with plenty of exercises that can be safely done at home. No pieces of exercise instruments or equipments are needed for people to perform these exercises for their joint pain relief and strengthening purposes.

Recipes To Support Healthy Joints

Much of the techniques used by the creator of Joint Pain Relief Codes are retrieved from fitness and nutrition experts. Besides that, people need to respect their body and make adjustments according to their joint pain symptoms. When the pain is well-controlled, it is favorable for them to engage in scheduled exercises on regular basis. Joint Pain Relief Codes is one program which comes with a diet plan that contains a number of food items to support healthy joints.

MUST READ: Joint Pain Relief Codes Reviews – ‘Don’t Buy It Without Reading This’

Jonathan Bender has identified a number of foods that can help control a person’s joint pain, strengthen their bones and boost the immune system. According to Jonathan, adding these food items to the balanced diet may help ease the symptoms of a person’s mild to severe joint pain.

Plenty of pleasant-tasting recipes (almond freezes, smoothies and fresh salsa) are rendered inside this course so people can have more options on what to prepare for their day to day meals. Adding to its effectiveness, people can have more options of food to eat every single day which undoubtedly drives out the dullness and monotony of eating the same foods over and over again.

ALSO SEE: Does Joint Pain Relief Codes Really Work? Read What Users Are Saying Here!

It is important to have a good understanding of what foods people should eat when they are battling against joint pain. As by knowing which foods to eat, they can help scale down their ache, stiffness, rigidity and swelling. Joint Pain Relief Codes is a complete guidebook and all the exercises and stretches recommended in it have no harmful side effects like medicaments that may give people a difficult time from battling this condition, the creator claims.

In addition, people will get helpful pieces of information from this program including yoga and meditation techniques to manage stress while also releasing physical tension. This e-book is reasonably priced, and users get to receive the primary e-book along with additional bonus items.

There are zero risks for people when they are purchasing Joint Pain Relief Codes as it comes with a 60-day money back refund policy which will greatly place the interest of buyers all over the world. If in case customers are not self-satisfied with the results it delivers, they can ask for a full refund of their money. Interested folks should hop over to the official website given below.

Visit Joint Pain Relief Codes Official Website Here!

SOURCE: Health Diaries

ReleaseID: 440976

NEW YORK, NY / ACCESSWIRE / June 9, 2016 / Princeton Nutrients™ introduces a new nutritional supplement “VitaPulse™” for cardiac health and support. This report by Healthy USA covers latest information revealed about the product.

VitaPulse™, by Princeton Nutrients™, has recently hit the market with its advanced anti-oxidant formula to provide Cardio protection and control cholesterol in the body. Healthy USA is an independent research and review organization and does not work for Princeton Nutrients™ but receives compensation from them.

Keller Jenny from Healthy USA reports about Princeton Nutrients’™ VitaPulse™

“After the success of “UltraKrill”, an omega 3 fatty acid supplement, Princeton Nutrients™ has manufactured another supplement, “VitaPulse™”, to provide ultimate heart protection by improving circulatory functions in the body. The three main ingredients that are used in VitaPulse™ are NAC, PQQ and CoQ10, which are highly beneficial for cardiovascular system. This supplement contains a blend of these vitamin-based-antioxidants to target free radicals and oxidation in order to improve not just heart functions, but overall health of the body,” reports Keller.

Access This News Report by Keller Catheryne Examining Dr. Bereliani’s Vitapulse™

When asked about the special ingredients of VitaPulse™, Dr Arash Bereliani, chief advisor of Princeton Nutrients™ explains: “VitaPulse™ is a blend of several useful anti-oxidants, including NAC, PQQ and CoQ10, which makes it a reliable heart health supplement due to its natural ability of cardiovascular protection. We have researched thoroughly in the medical field to find reliable resources which produce ingredients that help in strengthening heart functions. One such ingredient is N-acetyl-L-cysteine (NAC), which is highly effective in controlling cholesterol, especially lipoprotein.”

“Pyrroloquinoline quinone (PQQ) is a chemical which protects mitochondria from oxidation and toxic effects of amyloid, also it triggers the production of new mitochondria in human cells. It augments delicate mitochondrial structures to promote strong cellular functions,” he adds.

SPECIAL: 4 Stages to a Heart Attack – Check Your Risk Here!

Describing the benefits of CoQ10, Dr Bereliani further explains: “CoQ10 is the kind of antioxidants that can be taken by people who smoke or drink. Its supplementation significantly improves survival for cardiac arrest or heart failure patients while radically playing its role in reducing incidences of hospitalization. Its intake may extend lifespan and improves quality of life. It is also used in energy supplements for fitness conscious people.”

“VitaPulse™ makes the best use of NAC, PQQ and CoQ10 by including them in their advanced formula to help support healthy heart and circulatory system. VitaPulse™ supplement is suitable for people who have high-cholesterol or stress/anxiety problems. One capsule daily can invigorate heart functions.”

The Cardiac Killer: Is It Lurking Inside Of You? (Watch Video)

Keller further reports, “Apart from cardio-protection and cholesterol control, VitaPulse™ may provide other health benefits as well, such as reduction in joint pain and knee pain, dizziness and benefits for an active body.”

Dr Bereliani advice, “The risk of heart disease is quite high these days due to various reasons; unhealthy diet, no exercise habit, Stress/Anxiety, over consumption of alcohol and drugs, smoking etc. Along with a heart support supplement, a healthy diet and daily exercise is also required to deal with cardiac problems. Daily walking and taking sufficient amount of fruits and vegetables in daily meal can maximize the positive results of the supplement you’re taking.”

Read More : How Do I Know If Vitapulse Will Work For Me?

When asked about who cannot use VitaPulse™, Dr Arash says, “People with heart disease should talk to their doctor first and continue taking the prescribed medicines before taking VitaPulse™. Also, people who are already getting sufficient amount of NAC, PQQ and CoQ10 from other sources, don’t have to take VitaPulse™.”

“There are 30 capsules in one bottle of VitaPulse™, each containing 100mg of CoQ10, 250mg of NAC and 10mg of PQQ. Princeton Nutrients™ is offering discount rates on their packages of VitaPulse™ which are as follows; 1 Month Supply of 30 Capsules costs $49 + $6.95 for shipping, 3 month supply of 90 Capsules makes it $127 with free shipping and 6 Bottles carrying 180 Capsules cost $235 with free shipping.”

“It is also advised to buy the product from trusted source only i.e the official website of Princeton Nutrients. Concerning the quality of the product, sometimes, even the vendors at trusted online retailers cannot be trustworthy enough to buy supplements from, hence it is safe to buy it from its official website only, which is http://princetonnutrients.com/products/vitapulse.php“

About Princeton Nutrients: Princeton Nutrients™ LLC is a new name in the health industry but, because of the success of UltraKrill, its first supplement, it didn’t take much long for the company to create its brand image in the market. Dr. Arash Bereliani, the chief health adviser of the company, calls it a new initiative in the field of research and health development. For further queries, email at support@princetonnutrients.com

Vitapulse™ By Princeton Nutrients™ Official Website Link

About Healthy USA

Healthy USA is an independently owned company situated in New York, NY that assists consumers to find user-based information on specified products and services to help individuals determine if those specific products and services are in fact a suitable fit for them.

SOURCE: Healthy USA

ReleaseID: 440977

LOS ANGELES, CA / ACCESSWIRE / June 9, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Ability, Inc. (“Ability” or the “Company”) (Nasdaq: ABIL) concerning possible violations of federal securities laws between September 8, 2015 and April 29, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 25, 2016, lead plaintiff motion deadline.

To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company failed to disclose that: (1) Ability overstated its income by not accounting for commissions; and (2) Ability materially overstated its operating results by improperly recognizing revenue on multiple element sales transactions.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlaw.com

SOURCE: Lundin Law PC

ReleaseID: 440975

IRVINE, CA / ACCESSWIRE / June 9, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Intrexon Corporation (“Intrexon” or the “Company”) (NYSE: XON). Investors who purchased or otherwise acquired shares between May 12, 2015 and April 20, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm prior to the July 5, 2016, lead
plaintiff motion deadline.

If you purchased shares of Intrexon during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) Intrexon was overstating its revenue; and (2) as a result, Defendants’ statements about Intrexon’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 440974

NAPA, CA / ACCESSWIRE / June 9, 2016 / Bank of Napa, N.A. (OTCQB: BNNP) (“Company”), announced today that it has gained the approval of its shareholders and the Office of the Comptroller of the Currency to implement a stock repurchase program. Under the repurchase program, the Company may repurchase up to $2,750,000 of its common stock, or approximately 10% of the current outstanding shares based on recent trading prices.

The repurchase program permits shares to be repurchased in open market or private transactions until the earlier of June 8, 2017 or the Company’s repurchase of $2,750,000 of its common stock.

Repurchases will be made at management’s discretion at prices management considers to be attractive and in the best interests of both the Company and its shareholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and the Company’s financial performance.

The repurchase program may be suspended, terminated or modified at any time for any reason, including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The repurchase program does not obligate the Company to purchase any particular number of shares.

Bank of Napa, N.A. offers a complete range of loan and deposit products, and services to businesses and consumers in the Napa Valley. It operates two full service offices: at the corner of Redwood Road and Solano Avenue at 2007 Redwood Road, Suite 101; and at Second and Seminary Streets at 1715 Second Street, in Napa CA. Bank of Napa is a member of the FDIC. Its common stock is traded on the Over the Counter Bulletin Board under the symbol BNNP and the Company can be found on the web at www.thebankofnapa.com.

Contact Information:

Tom LeMasters
President & CEO
707-257-7777

Information contained herein may contain certain forward-looking statements that are based on management’s current expectations regarding economic, legislative, and regulatory issues that may impact the Company’s earnings in future periods. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include the words “believe,” “expect,” “intend,” “estimate” or words of similar meaning, or future or conditional verbs such as “will,” “would,” “should,” “could” or “may.” Factors that could cause future results to vary materially from current management expectations include, but are not limited to, general economic conditions, changes in interest rates, deposit flows, real estate values, and competition; changes in accounting principles, policies or guidelines; changes in legislation or regulation; and other economic, competitive, governmental, regulatory and technological factors affecting the Company’s operations, pricing, products and services. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

SOURCE: Bank of Napa, N.A.

ReleaseID: 440883

RIVER EDGE, NJ / ACCESSWIRE / June 9, 2016 / Nephros, Inc. (OTCQB: NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has completed a private placement of unsecured promissory notes and warrants to purchase the Company’s common stock resulting in total gross proceeds to the Company of approximately $1.2 million.

The outstanding principal under the notes accrues interest at a rate of 11% per annum. The Company is required to make interest only payments on a semi-annual basis, and all outstanding principal under the notes is repayable in cash on the third anniversary of the date of issuance. In addition to the promissory notes, the Company issued to the investors warrants to purchase approximately 2.4 million shares of common stock. The warrants have an exercise price of $0.30 per share and are exercisable for 5 years from the issuance date.

“We expect to see the initial revenue impact of our new products in the third quarter with significant growth through the end of this year,” said Daron Evans, President and Chief Executive Officer of the Nephros. “We appreciate the continued support of our investors to provide working capital as we progress toward becoming a cash-flow positive company.”

The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors.

This release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

Further details of the placement will be described in a Current Report on Form 8-K to be filed with the SEC by the Company and all of the transaction documents will be attached to the Form 8-K.

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.

For more information about Nephros, please visit the company’s website at www.nephros.com.

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to generate positive cash flows, expected revenue from new products and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including potential delays in the regulatory approval process, changes in business, economic and competitive conditions, the availability of capital when needed, our dependence on third party manufacturers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.’s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2015. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.

Contact:

Investor:
PCG Advisory Group
Kirin M. Smith, Chief Operating Officer
Direct: 646-863-6519
www.pcgadvisory.com

SOURCE: Nephros, Inc.

ReleaseID: 440973